

Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar

March 6, 2015

ATTORNEYS

Ropka, PhD, Stacie

PRACTICE AREAS

Intellectual Property

Brenda Sandburg The Pink Sheet

Axinn Counsel Stacie Ropka was quoted in The Pink Sheet's article, "Now Comes the Hard Part: Sandoz Must Sell Its Biosimilar." The Pink Sheet is produced by Pharma & Med Tech Business Intelligence.

Click here to access the article. A subscription is required.



© 2024 AXINN, VELTROP & HARKRIDER LLP